REGENXBIO Inc.
RGNX
$12.59
$0.383.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 161.32M | 155.78M | 156.72M | 83.33M | 84.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 161.32M | 155.78M | 156.72M | 83.33M | 84.33M |
| Cost of Revenue | 239.76M | 244.75M | 239.49M | 242.09M | 249.31M |
| Gross Profit | -78.44M | -88.96M | -82.77M | -158.76M | -164.98M |
| SG&A Expenses | 75.53M | 74.70M | 73.68M | 71.62M | 74.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 958.00K | 930.00K | 914.00K | 865.00K | 150.00K |
| Total Operating Expenses | 316.25M | 320.38M | 314.07M | 314.57M | 324.41M |
| Operating Income | -154.93M | -164.60M | -157.36M | -231.25M | -240.08M |
| Income Before Tax | -177.92M | -175.57M | -157.69M | -227.10M | -238.96M |
| Income Tax Expenses | -- | -- | -- | -- | -152.00K |
| Earnings from Continuing Operations | -177.92 | -175.57 | -157.69 | -227.10 | -238.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -177.92M | -175.57M | -157.69M | -227.10M | -238.81M |
| EBIT | -154.93M | -164.60M | -157.36M | -231.25M | -240.08M |
| EBITDA | -139.16M | -148.75M | -141.37M | -215.03M | -223.55M |
| EPS Basic | -3.46 | -3.44 | -3.11 | -4.61 | -5.03 |
| Normalized Basic EPS | -2.16 | -2.15 | -1.94 | -2.85 | -3.07 |
| EPS Diluted | -3.46 | -3.44 | -3.11 | -4.61 | -5.03 |
| Normalized Diluted EPS | -2.16 | -2.15 | -1.94 | -2.85 | -3.07 |
| Average Basic Shares Outstanding | 205.41M | 204.52M | 203.63M | 198.01M | 191.14M |
| Average Diluted Shares Outstanding | 205.48M | 204.59M | 203.71M | 198.01M | 191.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |